About Avik Pharmaceutical Limited
Data last updated: 05 January 2026
Avik Pharmaceutical Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 25 September 1979, the company has been in operation for over 47 years.
Registered with ROC Mumbai under CIN U99999MH1979PTC021711.
Capital: an authorised share capital of ₹12 Cr and a paid-up capital of ₹10.88 Cr. Formerly known as Avik Pharmaceuticals Limited and Avik Pharmaceuticals Private Limited. It is led by directors including Raj Kamal Prasad Verma and Anant Rajendralal Thakore.
Last AGM: 11 September 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹103.38 Cr, a growth of 29% compared to the previous year.
The company has a workforce of approximately 174 employees as per the latest available data.
The company is associated with 1 brand - Avik Pharmaceuticals. As per MCA filings, the company has open charges of ₹25.43 Cr and satisfied charges of ₹19.02 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website avikpharma.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressArvind Chambers Gauri Compound 188 Kurla Road Ground Floor Western Express Highway An, Dheri (E), Mumbai, Maharashtra, India – 400069
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Avik Pharmaceutical Limited
Avik Pharmaceutical Limited has undergone 2 name changes throughout its history. The company was previously known as Avik Pharmaceuticals Limited, and Avik Pharmaceuticals Private Limited. The current legal name is Avik Pharmaceutical Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Avik Pharmaceutical Limited | Current |
| Avik Pharmaceuticals Limited | Previous |
| Avik Pharmaceuticals Private Limited | Previous |
CIN History of Avik Pharmaceutical Limited
Avik Pharmaceutical Limited has one previous CIN (Corporate Identification Number): U99999MH1979PTC021711. The current CIN is U99999MH1979PLC021711, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U99999MH1979PLC021711 | Current |
| U99999MH1979PTC021711 | Previous |
Associated Brands with Avik Pharmaceutical Limited
Avik Pharmaceutical Limited operates one associated brand: Avik Pharmaceuticals. These brands represent Avik Pharmaceutical Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures corticosteroids and steroid APIs for pharmaceutical industry. | avikpharma.com |
Competitors & Alternatives of Avik Pharmaceutical Limited
Brands and companies operating in the same space as Avik Pharmaceutical Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Avik Pharmaceutical Limited
Avik Pharmaceutical Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Avik Pharmaceutical Limited
Avik Pharmaceutical Limited is currently managed by 8 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Raj Kamal Prasad Verma
Also directs:
Makers Laboratories Ltd, Resonance Specialties Limited, Evse Ready India Private Limited and 2 more
|
Director | 16 Sep 2024 | 1 Years 9 Months | Current |
|
Anant Rajendralal Thakore
Also directs:
Anantco Pharmachem Private Limited
|
Managing Director | 25 Sep 1979 | 46 Years 9 Months | Current |
| Sushil Kumar Kumra | Director | 16 Sep 2024 | 1 Years 9 Months | Current |
| Jeevan Lal Nagori | Director | 18 Nov 2013 | 12 Years 7 Months | Current |
|
Neha Anant Thakore
Also directs:
Anantco Pharmachem Private Limited, Themis Medicare Limited, Relic Technologies Limited and 1 more
|
Whole-Time Director | 04 Jan 2022 | 4 Years 6 Months | Current |
|
Rajeshree Maruti Chougule
Also directs:
Priya International Limited, Priya Limited
|
Company Secretary | 15 Nov 2024 | 1 Years 7 Months | Current |
Financials of Avik Pharmaceutical Limited FY 2025 filings available
Avik Pharmaceutical Limited reported revenue of ₹103.38 Cr (up 29% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Avik Pharmaceutical Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jun 2025 | Yes Bank Limited | ₹5 Cr | Open |
| 20 May 2015 | Yes Bank Limited | ₹20.43 Cr | Open |
| 21 Apr 1999 | Indian Bank | ₹12.39 Cr | Satisfied |
| 04 Mar 1998 | Central Bank of India | ₹1.3 Cr | Satisfied |
| 28 Apr 1994 | Indian Bank | ₹25 Lakh | Satisfied |
Total charge records: 23 View all charges
Employees and EPFO Compliance at Avik Pharmaceutical Limited
View historical data on people associated with Avik Pharmaceutical Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Avik Pharmaceutical Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Avik Pharmaceutical Limited
GSTIN & GST Filing Data of Avik Pharmaceutical Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Avik Pharmaceutical Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Avik Pharmaceutical Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Avik Pharmaceutical Limited
MSME Payment Delays by Avik Pharmaceutical Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Avik Pharmaceutical Limited
Subsidiaries & Group Companies of Avik Pharmaceutical Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Avik Pharmaceutical Limited with ownership details.
MCA Filings & Documents of Avik Pharmaceutical Limited
MCA Filings & Documents of Avik Pharmaceutical Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Avik Pharmaceutical Limited
Frequently Asked Questions about Avik Pharmaceutical Limited
Avik Pharmaceutical Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 25 September 1979 (47+ years old) and is registered under CIN U99999MH1979PLC021711. The company has 174 employees.
Avik Pharmaceutical Limited reported revenue of ₹103.38 Cr for FY 2025 (up 29.00% YoY).
The current directors of Avik Pharmaceutical Limited are:
- Raj Kamal Prasad Verma
- Anant Rajendralal Thakore
- Chandrashekar Koraga Shetty
- Sushil Kumar Kumra
- Jeevan Lal Nagori
- Neha Anant Thakore
- Rajeshree Maruti Chougule
- Sarita Loriknath Yadav
The primary industry of Avik Pharmaceutical Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Avik Pharmaceutical Limited can be reached at the registered office: Arvind Chambers Gauri Compound 188 Kurla Road Ground Floor Western Express Highway An, Dheri E, Mumbai, Maharashtra, India – 400069, or through the website avikpharma.com.
The authorised capital is ₹12 Cr, and the paid-up capital is ₹10.88 Cr.